Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 6Carcinoma, Ovarian Epithelial 3Melanoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Platinum-resistant Recurrent Ovarian Cancer 1Peritoneal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 61Cisplatin 45Cetuximab 32Radiotherapy 25Nivolumab 22Docetaxel 16Radiotherapy, Intensity-Modulated 14Paclitaxel 13Carboplatin 13durvalumab 11Radiation 10Fluorouracil 10Magnetic Resonance Spectroscopy 9Cyclophosphamide 9fludarabine 8Erlotinib Hydrochloride 8budigalimab 7Ipilimumab 7atezolizumab 6Radiosurgery 6Gemcitabine 6Drug Therapy 6130-nm albumin-bound paclitaxel 6tremelimumab 5tislelizumab 5spartalizumab 5fludarabine phosphate 5avelumab 5Surgical Procedures, Operative 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Squamous Cell Carcinoma of Head and Neck × 1-dodecylpyridoxal × Clear all
NCT04244552 2023-12-29

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Atreca, Inc.

Phase 1 Terminated
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡